spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Advertising

David Hirsh


 

Editorial 

Emma Naks
  

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.



View the
digital version
of EBR


ebr
 
 
Featured in this issue
THERAPEUTIC DEVELOPMENT
Companion Diagnostics

Testing Patients


Autoimmune diseases – such as lupus – remain difficult to treat. Protagen’s Petra Budde and Peter Schulz-Knappe hope that pharma will respond by aligning companion diagnostic development with clinical programmes.
Discovery Technology
Drug Repositioning

Same Drug: New Purpose


Repositioning has been used to speed up productivity issues in current drug development and address unmet patient needs. José Manuel Mas and Judith Farrés from Anaxomics take us through a few key approaches.
  CELL-BASED RESEARCH
Anti-Cancer Drug Delivery

Hitting the Mark


Research into cell biology has uncovered new ways of targeting specific drugs to reach cancer cells – improving patient outcomes and reducing side-effects. Aidan Seeley and Heather M Wallace at the University of Aberdeen go into more detail.

spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October
Banner of Eppendorf on Samedan
Banner of Samedan app.EBR on Samedan
 
Industry Events

Cancer Vaccines

16-17 September 2015, Marriott Regents Park Hotel, London UK

The 4th annual Cancer Vaccines conference will strengthen knowledge of targeted immunotherapies taking the foreground in revolutionizing cancer vaccines as well as look at the practicalities towards achieving sustained immune response.
More info >>

 
News and Press Releases

Quotient Clinical Reports Another Successful Year of Record Growth

Quotient’s Translational Pharmaceutics platform has been adopted by more than 30 new customers contributing to a year-on-year increase in revenue of 24%, with similar growth levels anticipated in the next 12 months.
More info >>

air transport logo

 

White Papers

Phase II trial of Trigemina’s TI-001 for high frequency migraine

Exco InTouch Ltd

Trigemina’s TI-001 is a patented application of a formulation including oxytocin with a novel mode of action (MOA) as a therapy for high frequency migraine. Open label data suggests that TI-001 holds the promise to be safe and effective in reducing moderate and severe headache day frequency among this population by more than 50%, with corresponding decreases in secondary migraine symptoms (nausea, vomiting etc.) and use of acute medications, a significant improvement compared to current drugs.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement